Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Milei Threatens Falkland Oil Firms With Sanctions 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
SpaceX Turbine Push Unlikely to Threaten Howmet, Bernstein Says 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Add as a preferred source on Google
BETHLEHEM, Pa., Feb. 26, 2018 -- OraSure Technologies, Inc. (NASDAQ:OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Douglas A. Michels, President and CEO, will speak to the investment community at the Raymond James 39th Annual Institutional Investors Conference. The conference will be simultaneously webcast over the Internet.
Mr. Michels is scheduled to speak on March 5, 2018, at approximately 10:25 AM Eastern Time (7:25 AM Pacific Time). Interested investors can access the live webcast of the presentation by going to OraSure Technologies’ web site, www.orasure.com and clicking on the Investor Info link. A replay of the webcast will be available on OraSure Technologies’ web site for seven days. Alternatively, you can access the live webcast of the presentation via the following link: http://wsw.com/webcast/rj108/osur
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture and distribution of point of care diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its first-to-market, innovative products include rapid tests for the detection of antibodies to HIV and HCV on the OraQuick® platform, oral fluid sample collection, and stabilization and preparation products for molecular diagnostic applications, and oral fluid laboratory tests for detecting various drugs of abuse. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, commercial and industrial entities and consumers. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. For more information on OraSure Technologies, please visit www.orasure.com.
Company contact:
Ronald H. Spair
Chief Financial Officer
610-882-1820
[email protected]
www.orasure.com
Shauna White
Corporate Marketing Manager
484-353-1575
[email protected]
www.orasure.com
